Riyadh, Saudi Arabia: MS Pharma Saudi Arabia, part of MS Pharma Group - One of the leading biopharmaceutical companies in the MENA region - sponsored the King Saud University Crossroads Career Event, held on 28 and 29 March, reaffirming its commitment to supporting and developing Saudi talent at the early stages of their professional journeys. Through its Talent Management team, alongside representatives from key business functions, MS Pharma engaged directly with high-potential fresh graduates, primarily from pharmacy and life sciences disciplines, as well as early-career professionals exploring opportunities within the pharmaceutical sector. 

Algiers, Algeria / Amman, Jordan —MS Pharma Group, a leading regional pharmaceutical company in the MENA region, has signed a strategic partnership agreement with Hetero Group, a global pharmaceutical company, to localize five established biosimilars across key therapeutic areas, including oncology, immunology and hematology. 

Algiers, Algeria — On Saturday, El Kendi Pharmaceutical Manufacturing facility, part of the regional MS Pharma Group, welcomed an Algerian ministerial delegation consisting of Ms. Kouthar Krikou, Minister of Environment and Quality of Life, and Mr. Kamel Baddari, Minister of Higher Education and Scientific Research, during a field visit to the facility’s production site.

Planegg-Martinsried, Germany / Amman, Jordan – Formycon AG (FSE: FYB, Prime Standard) and MS Pharma jointly announce that they have entered into an exclusive licensing and supply agreement for the commercialization of FYB206, Formycon’s biosimilar candidate to the blockbuster drug Keytruda^®1 (Pembrolizumab), in the Middle East and North Africa (“MENA region”). The agreement includes an option for future technology transfer. 

Riyadh, Saudi Arabia

MS Pharma has announced that its biologics manufacturing facility in Riyadh has officially obtained Good Manufacturing Practice (GMP) certification from the Saudi Food and Drug Authority (SFDA) in August 2025, following an inspection in June. This milestone positions the company as a trusted biologics partner for GCC, MENA, and global markets, while advancing Saudi Arabia’s Vision 2030 localization objectives.